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Abstract 
We read with great interest Henderson and colleagues’ paper in your journal (2009; 29:165–169), which 
reported that aripiprazole reduced olanzapine-induced overweight/obesity and hyperlipidemia in a 
10-week placebo-controlled double-blind crossover study. This and their previous studies, provide a new 
way for controlling olanzapine- and clozapine-induced weight gain/obesity using another atypical 
antipsychotic, even without reducing the original olanzapine and clozapine doses, which is important 
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 Editors,  
We read with great interest Henderson and colleagues’ paper in your journal (2009; 
29:165–169), which reported that aripiprazole reduced olanzapine-induced 
overweight/obesity and hyperlipidemia in a 10-week placebo-controlled double-blind 
crossover study. This and their previous studies 1,2 provide a new way for controlling 
olanzapine- and clozapine-induced weight gain/obesity using another atypical 
antipsychotic, even without reducing the original olanzapine and clozapine doses, 
which is important particularly for treatment of refractory schizophrenia patients. The 
key issue is what are the mechanisms that underlie aripiprazole’s effects on body 
weight? Henderson et al. proposed that aripiprazole’s low histaminergic antagonism 
and 5-HT2C agonist activity may contribute to its effect on reducing olanzapine-
induced weight gain 1.  
 
Several meta-analytical studies have indicated an association between histamine H1 
antagonism properties in antipsychotic drugs and obesity side-effects 3,4. Consistent 
with these findings, both olanzapine and clozapine are potent H1 antagonists 5. A 
recent study found that, correlated with body weight gain, olanzapine treatment 
significantly down-regulated H1 receptor binding and mRNA expression in the rat 
hypothalamus, however, aripiprazole did not affect H1 receptor expression 6. These 
results suggest that aripiprazole’s effects in reducing olanzapine- and clozapine-
induced weight gain/obesity should not be via H1 receptors, although histaminergic 
antagonism is a main cause of olanzapine- and clozapine-induced weight gain/obesity.  
 
We agree that 5-HT2C receptors may play a role, however, it should also be noted that 
aripiprazole has only a moderate affinity to 5-HT2C receptors 
7. Aripiprazole was 
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developed as a potent dopamine D2 partial-agonist, 5-HT1A partial agonist, and also 
5-HT2A antagonist 
7. A recent study has reported that both aripiprazole and olanzapine 
affect 5-HT1A receptor expression, but these changes are not correlated with body 
weight 8. On the other hand, like aripiprazole, olanzapine and clozapine are 5-HT2A 
antagonists 5. Recent studies have suggested that aripiprazole is not a simple partial 
agonist, but a functionally selective drug that can act as a D2 agonist or D2 antagonist 
in different brain regions 9,10. We suggest that aripiprazole’s D2 agonistic property 
may account partly for the effect of aripiprazole in reducing olanzapine-induced 
overweight /obesity. Atypical antipsychotics such as olanzapine may increase appetite 
through the dopamine-mediated reward pathway 11. Dopamine D2 agonists have been 
reported to reduce food intake by acting in hypothalamic areas 12.  
 
Another possible mechanism of aripiprazole may be via the activation of the 
PI3K/Akt pathway. The PI3K/Akt pathway plays an important role in cellular 
proliferation, growth and metabolism 13. Over-expression of the pathway causes 
cancer but defects in the pathway could induce metabolic disorders. The PI3K/Akt 
pathway plays a key role in the action of insulin via control of Glu4, which transports 
glucose into the cells 14. The activity of the PI3K/Akt pathway in insulin-mediated 
Glu4 activation is impaired in olanzapine-induced obesity 15. Aripiprazole may have 
an effect on the activation of the PI3K/Akt pathway via its agonistic effect on D2 
receptors. In fact, D2 receptor agonist (bromocriptine) has been reported to increase 
the PI3K/Akt pathway activity 16. It is possible that aripiprazole can restore the 
impairment of the PI3K/Akt pathway in insulin-mediated Glu4 activation caused by 
olanzapine so that the side-effect of weight gain is reduced. Further studies on these 
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mechanisms will improve our understanding and management of atypical 
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